DYMDF (Diamyd Medical AB) GF Value Rank: 2 (As of Aug. 10, 2026) — 100% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DYMDF Diamyd Medical AB DYMDF
41 GF Score
Price $0.73
GF Value $9.89
! 3 Warning Signs
View Full Analysis

What is Diamyd Medical AB GF Value Rank?

Diamyd Medical AB DYMDF 41 GF Value Rank is 2 as of Aug. 10, 2026, which is 100% above its 10-year median of 1.00. GuruFocus rates DYMDF with a GF Score™ of 41/100 and a GF Value™ of $9.89. The stock has 3 warning signs investors should review.

Diamyd Medical AB has the GF Value Rank of 2.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Diamyd Medical AB GF Value Rank Related Terms

DYMDF vs VRTX, REGN, RVMD: GF Value Rank Comparison

For the Biotechnology subindustry, Diamyd Medical AB's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diamyd Medical AB GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's GF Value Rank falls into.


DYMDF
41GF Score
Diamyd Medical AB DYMDF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 2 mean?
Diamyd Medical AB (DYMDF) has a GF Value Rank of 2 as of Aug. 10, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Diamyd Medical AB and its competitors. This is 100% above median its historical median of 1.00. Over the past decade, Diamyd Medical AB's GF Value Rank has ranged from 1.00 to 10.00.
Is Diamyd Medical AB's GF Value Rank too high?
Diamyd Medical AB's current GF Value Rank of 2 is 100% above median its 10-year median of 1.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Diamyd Medical AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's GF Value Rank compare to VRTX and REGN?
Diamyd Medical AB's GF Value Rank of 2 can be compared against companies in the Biotechnology industry. Historically, Diamyd Medical AB's own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Diamyd Medical AB and its competitors. Diamyd Medical AB's current GF Value Rank is 2, which is 100% above median its own 10-year median of 1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Diamyd Medical AB (DYMDF) has a current GF Value Rank of 2. The stock's GF Value™ is $9.89, compared to a current price of $0.73 — trading 92.6% below its estimated fair value. The current GF Value Rank is 2, which is 100% above median its 10-year median of 1.00. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Diamyd Medical AB (DYMDF), the current GF Value Rank is 2 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diamyd Medical AB (DYMDF) Overvalued in 2026?

Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued. The current stock price of $0.73 is trading 92.6% below its estimated GF Value™ of $9.89.

Key valuation signals for DYMDF:

  • GF Value Rank: 2 (100% above median its 10-year median of 1.00)
  • GF Value™: $9.89 vs. price of $0.73 (92.6% below fair value)
  • GF Score™: 41/100 with 3 warning signs

No single metric tells the full story. See the DYMDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diamyd Medical AB Business Description

Other Exchanges DMYD B:SwedenDMN:Germany
Address Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score

Get the complete analysis for DYMDF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.73
Price
$9.89
GF Value